

Baseline Characteristics of Participants in the Phase 3 ARCHER II Trial in Dry AMD with GA

Ashkan Abbey MD¹

On behalf of the ARCHER and ARCHER II Investigators

¹Director of Clinical Research, Texas Retina Associates, Dallas, TX

Disclosures

I have the following financial interests or relationships to disclose:

Alcon Laboratories, Inc.: Consultant/Advisor

ANI: Consultant/Advisor

Abbvie: Consultant/Advisor, Grant Support

Annexon: Consultant/Advisor

Apellis Pharmaceuticals, Inc.: Lecture Fees/Speakers Bureau

Astellas: Lecture Fees/Speakers Bureau

Bausch + Lomb: Consultant/Advisor

BVI : Consultant/Advisor

EyePoint Pharmaceuticals: Consultant/Advisor, Grant Support

GENENTECH: Consultant/Advisor

Harrow: Consultant/Advisor

Neurotech: Consultant/Advisor

Regeneron Pharmaceuticals, Inc.: Consultant/Advisor, Lecture Fees/Speakers Bureau

Ocular Therapeutix: Consultant/Advisor

ARCHER: Phase 2 Trial Of The C1q Inhibitor Vonaprument (ANX007) in Patients with Dry AMD and GA

Randomized, double-masked
Included **foveal and non-foveal** lesions
Stratified for lesion location and lesion size
12 months (n=270)

Sham
monthly or every other month
(n=89)

Vonaprument 5mg
every other month (EOM)
(n=92)

Vonaprument 5mg
monthly (EM)
(n=89)

PRIMARY ENDPOINT

Rate of Change in GA lesion area as assessed
by fundus autofluorescence at Month 12

PRESPECIFIED FUNCTIONAL ANALYSES

Best Corrected Visual Acuity (BCVA)
Low Luminance Visual Acuity (LLVA) & Deficit (LLVD)


Off-treatment
(6 months)

END OF STUDY
Month 18

ARCHER Phase 2: Dose-Dependent Vision Protection at Month 12 and Over Time


PARTICIPANTS WITH CONFIRMED BCVA ≥ 15 -LETTER LOSS THROUGH MONTH 12[#]

Month 12 event confirmed at month 15



[#]Confirmed BCVA 15-LL at two consecutive visits including month 12 supported by ensuing (off-treatment) visit; visits were monthly through Month 12 and then at Months 15 and 18
[^]Nominal p-value from a Chi-square test in ITT population: *Nominal p < .05

PROBABILITY OF CONFIRMED BCVA ≥ 15 -LETTER LOSS THROUGH MONTH 12[#]




[#]Confirmed BCVA 15-LL at two consecutive visits including month 12 supported by ensuing (off-treatment) visit
HR, hazard ratio; Nominal log-rank test (versus sham) p-values are presented; *Nominal p < 0.05\

ARCHER Phase 2: Dose-Dependent Vision Protection in Both Healthier and Less Healthy Eyes

Profound effect seen in treating healthier eyes


PARTICIPANTS WITH CONFIRMED BCVA $\geq$ 15-LETTER LOSS THROUGH MONTH 12[#]



[#]15-LL Event Definition – confirmed loss of 15 or more letters by BCVA at two consecutive visits including month 12 supported month 15; Events: n = 27


ARCHER Phase 2: Dose-Dependent Vision Protection in Participants with Foveal and Non-Foveal Lesions

PARTICIPANTS WITH CONFIRMED BCVA ≥ 15 -LETTER LOSS THROUGH MONTH 12[#]




[#]15-LL Event Definition – confirmed loss of 15 or more letters by BCVA at two consecutive visits including month 12 supported month 15; Events: n = 27

Key ARCHER Attributes Replicated in Larger, Longer ARCHER II Design



PRIMARY ENDPOINT

Rate of change in GA lesion area as assessed by fundus autofluorescence at Month 12



PRIMARY ENDPOINT

Proportion of patients who experience a BCVA ≥ 15 -Letter Loss confirmed at two consecutive visits at Month 15 or Month 24

ARCHER II Participant Demographics and Structural Characteristics Consistent with ARCHER Population

BASELINE DEMOGRAPHICS AND STRUCTURAL CHARACTERISTICS	ARCHER (N = 270)	ARCHER II (N = 659)
Age, mean (SD)	80.0 (8.2)	78.4 (8.0)
Gender (% Female)	61.5%	63.0%
GA Lesion Size (mm ²), mean (SD)	7.36 (4.01)	7.23 (3.49)
GA Lesion Location (% Subfoveal)	51.9%	54.8%
Total EZ Loss, mm ² (% of Total Area Lost)	12.7 (35.3%)	12.3 (34.3%)

ARCHER II Baseline Visual Acuity Compared to ARCHER Consistent with Exclusion of Low Vision Subjects (BCVA <45)

BASELINE VISUAL ACUITY MEASURES	ARCHER (N = 270)	ARCHER II (N = 659)
Mean BCVA (SD)	58.4 (16.2)	65.8 (10.5)
Baseline BCVA <45 Letters	23.3%	0.0%*
15-LL Events w Baseline BCVA <45 Letters	1	--
15-LL Events w Baseline BCVA ≥45 Letters	26	--
Mean LLVA (SD)	33.0 (16.9)	38.3 (17.2)
Mean LLVD (SD)	25.7 (16.9)	27.6 (15.6)
LLVD < 30 Letters	62.4%	60.7%

*Individuals with baseline BCVA <45 letters not enrolled in ARCHER II
due to very low incidence of BCVA 15-letter loss in ARCHER

ARCHER II Study Design Optimized to Assess Vision Protection

- ARCHER demonstrated dose dependent vision protection with vonaprumment treatment across key measures of visual acuity and across patient populations
- ARCHER II design consistent with ARCHER study demographics and baseline characteristics
- ARCHER II population replicates those with large treatment effects seen in ARCHER
 - Foveal lesions at baseline: more than 50% of the study population
 - Baseline LLVD < 30: more than 60% of the study population
- Anticipated communications on track for Month 15 primary endpoint in Q4 2026 and Month 24 primary endpoint in Q3 2027